PHT Corporation LogPad System Selected by Agile Therapeutics for Use in its Phase III Trial of Twirla Investigational Contraceptive Patch

PHT Corporation, a leading provider of technologies used to collect patient-driven eData for clinical research, announced today that its LogPad® System has been selected by Agile Therapeutics for use in its SECURE Phase III trial for its investigational product candidate, Twirla®.   

The LogPad System is the world’s most widely-used electronic patient reported outcome (ePRO) eDiary for patient-focused eClinical research that speeds the delivery of new drugs and therapies. Sponsors, clinicians and patients rely on the LogPad System for ease of use, simplicity, PHT’s regulatory compliance, and data integrity.

Twirla is an investigational once weekly contraceptive patch, which delivers the hormones levonorgestrel and ethinyl estradiol over a seven-day period.  As a weekly regimen, Twirla is designed to offer convenience and promote enhanced patient compliance.

Elizabeth I. O. Garner, MD, MPH, Chief Medical Officer and Senior Vice President of Clinical Development at Agile Therapeutics, said, “Agile chose the LogPad System for its proven track record of data quality and security, and for the comfort and convenience it offers our patients. We chose PHT for its leadership and experience in delivering eClinical Systems and for its excellent customer service.”

PHT Vice President of Marketing and Corporate Strategy Sheila Rocchio, MBA said, “Market adoption of ePRO systems is growing as more trial sponsors use technology to accelerate the clinical development process. PHT is passionate about helping researchers do great science to improve outcomes and quality of life. We appreciate the opportunity to work with Agile on this innovative new product.”
 

The LogPad System has been a finalist for the Massachusetts Technology Leadership Council Innovative Healthcare and Life Sciences Technology of the Year, SCDM Innovation, and Clinical Informatics News awards.